Acusphere (OTCMKTS:ACUS) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison

Oramed Pharmaceuticals (NASDAQ:ORMP) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Oramed Pharmaceuticals and Acusphere’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-7.27%	-6.20%
Acusphere	N/A	N/A	N/A

Institutional & Insider Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Acusphere shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Oramed Pharmaceuticals and Acusphere”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2.00 million	43.71	$5.53 million	($0.44)	-4.86
Acusphere	N/A	N/A	N/A	N/A	N/A

Oramed Pharmaceuticals has higher revenue and earnings than Acusphere.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Oramed Pharmaceuticals and Acusphere, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Acusphere	0	0	0	0	0.00

Given Acusphere’s higher possible upside, analysts plainly believe Acusphere is more favorable than Oramed Pharmaceuticals.

Risk & Volatility

Oramed Pharmaceuticals has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Acusphere has a beta of -1.2, meaning that its stock price is 220% less volatile than the S&P 500.

Summary

Oramed Pharmaceuticals beats Acusphere on 5 of the 8 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.